JY
ABCL icon

Jeff Yass’s AbCellera Biologics ABCL Stock Holding History

Jeff Yass’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$162K Sell
20,580
-729,813
-97% -$3.57M ﹤0.01% 12146
2026
Q1 		$2.62M Sell
750,393
-774,170
-51% -$2.79M ﹤0.01% 5561
2025
Q4 		$5.21M Buy
1,524,563
+106,030
+7% +$473K ﹤0.01% 3946
2025
Q3 		$7.14M Buy
1,418,533
+824,245
+139% +$3.63M ﹤0.01% 3531
2025
Q2 		$2.04M Buy
594,288
+345,643
+139% +$860K ﹤0.01% 5739
2025
Q1 		$554K Sell
248,645
-168,751
-40% -$484K ﹤0.01% 8672
2024
Q4 		$1.22M Buy
417,396
+183,332
+78% +$511K ﹤0.01% 6469
2024
Q3 		$609K Sell
234,064
-14,684
-6% -$40.7K ﹤0.01% 7990
2024
Q2 		$736K Buy
248,748
+26,690
+12% +$101K ﹤0.01% 7303
2024
Q1 		$1.01M Sell
222,058
-113,934
-34% -$581K ﹤0.01% 6908
2023
Q4 		$1.92M Buy
335,992
+95,767
+40% +$444K ﹤0.01% 5449
2023
Q3 		$1.11M Sell
240,225
-298,781
-55% -$1.82M ﹤0.01% 6414
2023
Q2 		$3.48M Buy
539,006
+385,667
+252% +$2.63M ﹤0.01% 4121
2023
Q1 		$1.16M Sell
153,339
-12,770
-8% -$116K ﹤0.01% 6433
2022
Q4 		$1.68M Buy
166,109
+106,065
+177% +$1.23M ﹤0.01% 5044
2022
Q3 		$594K Buy
+60,044
New +$659K ﹤0.01% 8023
2022
Q2 		– Sell
-128,512
Closed -$1.09M – 12758
2022
Q1 		$1.25M Sell
128,512
-285,901
-69% -$2.71M ﹤0.01% 6574
2021
Q4 		$5.93M Sell
414,413
-19,967
-5% -$303K ﹤0.01% 3471
2021
Q3 		$8.71M Buy
434,380
+201,554
+87% +$3.56M ﹤0.01% 3072
2021
Q2 		$5.12M Buy
232,826
+162,626
+232% +$4.48M ﹤0.01% 3993
2021
Q1 		$2.38M Buy
70,200
+49,105
+233% +$1.96M ﹤0.01% 5488
2020
Q4 		$849K Buy
+21,095
New +$965K ﹤0.01% 7086

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Jeff Yass's ABCL Position: Q2 2026 in Review

Jeff Yass reduced its AbCellera Biologics (ABCL) stake by 97% in Q2 2026, selling an estimated $3.57M and leaving 20,580 shares worth $162K. The position accounts for ﹤0.01% of the portfolio, ranked #12146.

Jeff Yass first reported a position in ABCL in Q4 2020 and has held it in 22 quarters since. The position peaked at $8.71M in Q3 2021. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Jeff Yass held 20,580 shares of AbCellera Biologics worth $162K as of Q2 2026.
  • Jeff Yass sold 729,813 AbCellera Biologics shares in Q2 2026, an estimated $3.57M.
  • AbCellera Biologics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12146 holding.
  • Jeff Yass first reported a position in AbCellera Biologics in Q4 2020 and has held it in 22 quarters since.
  • Jeff Yass's AbCellera Biologics position peaked at $8.71M in Q3 2021.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.